Bayer Healthcare has nabbed a deal with Nektar Therapeutics to develop and commercialize Nektar's remedy for gram-negative pneumonia, known as inhaled amikacin. Bayer will pay $50 million up front, plus an additional $125 million in milestone payments if they successfully bring the compound to market. Profits on eventual U.S. sales will be shared 50-50.
- check out the release
Nektar settles university patent fight. Report
Nektar gains fast track for lung infection drug. Report